Literature DB >> 7690505

Neutralizing epitopes of African horsesickness virus serotype 4 are located on VP2.

T G Burrage1, R Trevejo, M Stone-Marschat, W W Laegreid.   

Abstract

A panel of monoclonal antibodies (MAbs) was generated against African horsesickness virus serotype 4 (AHSV/4). Three of the MAbs (SA6, OH3, and ME11) strongly neutralized the homologous virus and a heterologous type 4 isolate. The MAbs did not cross-neutralize AHS serotypes 1-3 or 5-9. The MAbs immunoprecipitated a viral protein of 108 kDa which co-migrated with VP2. Pretreatment with SA6 prevented mortality of 71% of day-old mice after intracranial injection of 100 LD50 of AHSV/4, while OH3 and ME11 significantly increased the average survival time of challenged animals. This study demonstrates that neutralizing epitope(s) for AHS are located on VP2 and that antibodies to these epitope(s) are protective in a neonatal mouse model.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690505     DOI: 10.1006/viro.1993.1537

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

1.  Structural insight into African horsesickness virus infection.

Authors:  Violeta Manole; Pasi Laurinmäki; Wouter Van Wyngaardt; Christiaan A Potgieter; Isabella M Wright; Gert J Venter; Alberdina A van Dijk; B Trevor Sewell; Sarah J Butcher
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

2.  Serologic markers in early stages of African horse sickness virus infection.

Authors:  J L Martínez-Torrecuadrada; M Díaz-Laviada; P Roy; C Sánchez; C Vela; J M Sánchez-Vizcaíno; J I Casal
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

3.  Structural Protein VP2 of African Horse Sickness Virus Is Not Essential for Virus Replication In Vitro.

Authors:  René G P van Gennip; Sandra G P van de Water; Christiaan A Potgieter; Piet A van Rijn
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

4.  A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse model.

Authors:  Javier Castillo-Olivares; Eva Calvo-Pinilla; Isabel Casanova; Katarzyna Bachanek-Bankowska; Rachael Chiam; Sushila Maan; Jose Maria Nieto; Javier Ortego; Peter Paul Clement Mertens
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

5.  Serotype specific primers and gel-based RT-PCR assays for 'typing' African horse sickness virus: identification of strains from Africa.

Authors:  Narender S Maan; Sushila Maan; Kyriaki Nomikou; Manjunatha N Belaganahalli; Katarzyna Bachanek-Bankowska; Peter P C Mertens
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

6.  Immunogenicity of recombinant VP2 proteins of all nine serotypes of African horse sickness virus.

Authors:  Yuta Kanai; Piet A van Rijn; Mieke Maris-Veldhuis; Yuki Kaname; T N Athmaram; Polly Roy
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

7.  The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host.

Authors:  Eva Calvo-Pinilla; Simon Gubbins; Peter Mertens; Javier Ortego; Javier Castillo-Olivares
Journal:  Antiviral Res       Date:  2018-04-18       Impact factor: 5.970

8.  Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Assay for the Rapid Detection of African Horse Sickness Virus.

Authors:  V L Fowler; E L A Howson; J Flannery; M Romito; A Lubisi; M Agüero; P Mertens; C A Batten; H R Warren; J Castillo-Olivares
Journal:  Transbound Emerg Dis       Date:  2016-08-02       Impact factor: 5.005

9.  Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).

Authors:  Rachael Chiam; Emma Sharp; Sushila Maan; Shujing Rao; Peter Mertens; Barbara Blacklaws; Nick Davis-Poynter; James Wood; Javier Castillo-Olivares
Journal:  PLoS One       Date:  2009-06-22       Impact factor: 3.240

10.  Ns1 is a key protein in the vaccine composition to protect Ifnar(-/-) mice against infection with multiple serotypes of African horse sickness virus.

Authors:  Francisco de la Poza; Eva Calvo-Pinilla; Elena López-Gil; Alejandro Marín-López; Francisco Mateos; Javier Castillo-Olivares; Gema Lorenzo; Javier Ortego
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.